PROCEPT BioRobotics Corporation
NASDAQ:PRCTMedical - Devices
+$0.19 today
- Market cap
- $1.45B
- Beta
- 0.85
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.81
Volume 2.05M
Average 1.46M
PRCT Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
PROCEPT BioRobotics CorporationNASDAQ: PRCT
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $41.04M (cash outflow) rose 118.1% year over year, ahead of the -8.7% change in trailing-twelve-month free cash flow. Sequentially, it rose 237.0% from the prior quarter. Over 3 fiscal years it compounded at -11.1% a year.
Context
- Free cash flow amounted to 18.9% of revenue in FY2025, down 27.2 pp from a year earlier.
- Free cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +118.1% holds above the trailing-twelve-month pace of -8.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (58.34M) USD
- Year-over-year change
- +43.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (58.34M) | +43.7% |
| FY2024 | 2024-12-31 | (103.62M) | +22.2% |
| FY2023 | 2023-12-31 | (133.21M) | -60.4% |
| FY2022 | 2022-12-31 | (83.04M) | -43.3% |
| FY2021 | 2021-12-31 | (57.93M) | — |
Free Cash Flow vs competitors
How PRCT compares with its peers on the latest reported figures
- PRCT's LTM Mar 2026 free cash flow of $80.57M is the largest of the 5 companies compared; the peer median is $17.54M.
- Its year-over-year change of -8.7% is the lowest of 4, against a peer median of +65.3%.
- Free cash flow amounts to 25.0% of revenue for PRCT, versus a peer median of 51.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $80.57M | -8.7% | -11.1% | 25.0% | |
| LTM Mar 2026 | $26.7M | +127.5% | +14.2% | 65.8% | |
| LTM Mar 2026 | $17.59M | +22.7% | +149.1% | 36.3% | |
FOCLEDAP TMS S.A. American Depositary Shares | LTM Jun 2024 | $17.48M | — | +77.6% | 26.1% |
| LTM Mar 2026 | $15.38M | +65.3% | +4.1% | 14647.6% | |
| Peer median (excluding PRCT) | $17.54M | +65.3% | +45.9% | 51.0% | |
Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.57M) |
| Depreciation & Amortization | 3.32M | 2.84M | 3.81M | 5.23M | 6.39M |
| Deferred Income Tax | 451K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.8M | 10.34M | 19.13M | 31.84M | 47.6M |
| Change in Working Capital | (4.71M) | (11.49M) | (26.16M) | (47.33M) | (7.84M) |
| Accounts Receivables | (2.91M) | (10.81M) | (33.1M) | (35.96M) | (898K) |
| Inventory | (6.12M) | (15.25M) | (9.75M) | (17.24M) | (14.5M) |
| Accounts Payables | 812K | 3.96M | 5.79M | (2.15M) | 6.65M |
| Other Working Capital | 3.52M | 10.61M | 10.9M | 8.02M | 909K |
| Other Non-Cash Items | (345K) | 5.08M | 1.12M | 2.45M | 433K |
| Operating Cash Flow | (57.33M) | (80.38M) | (108M) | (99.21M) | (48.99M) |
| Capital Expenditures | (592K) | (2.65M) | (25.21M) | (4.41M) | (9.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (592K) | (2.65M) | (25.21M) | (4.41M) | (9.36M) |
| Debt Repayment | 0 | 1.2M | 0 | 0 | 0 |
| Common Stock Issued | 172.36M | 0 | 161.71M | 164.52M | 11.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.04M | 2.42M | 6.09M | 15.6M | 0 |
| Financing Cash Flow | 262.12M | 3.61M | 167.8M | 180.13M | 11.19M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (74K) |
| Net Change in Cash | 204.19M | (79.42M) | 34.59M | 76.5M | (47.22M) |
| Free Cash Flow | (57.93M) | (83.04M) | (133.21M) | (103.62M) | (58.34M) |
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
Intrinsic Alpha fair value
Locked
Current Price
$25.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.